Status:
WITHDRAWN
Fingolimod in COVID-19
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University
Conditions:
Coronavirus Disease (COVID-19)
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Although immune-inflammatory treatment is not routinely recommended to be used for SARS-CoV-2 pneumonia, according to the pathological findings of pulmonary oedema and hyaline membrane formation, time...
Eligibility Criteria
Inclusion
- The patients who were diagnosed with the common type of NCP (including severe risk factors) and severe cases of new coronavirus pneumonia;
- Aged 18 to 85 years;
- Patients or authorized family members volunteered to participate in this study and signed informed consent.
Exclusion
- Patients with any history of bradyarrhythmia or atrioventricular blocks
- Patients who are participating in other drug clinical trials;
- Pregnant or lactating women;
- ALT / AST\> 5 ULN, neutrophils \<0.5, platelets less than 50;
- Definite diagnosis of rheumatic immune-related diseases;
- Long-term oral anti-rejection or immunomodulatory drugs;
- Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.
Key Trial Info
Start Date :
February 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04280588
Start Date
February 22 2020
End Date
July 1 2020
Last Update
November 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wan-Jin Chen
Fuzhou, China